Profile for Austria Patent: E514689

US Patent Family Members and Approved Drugs for Austria Patent: E514689

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,163,904	Feb 23, 2029	Novartis	TASIGNA	nilotinib hydrochloride
8,389,537	Jan 18, 2027	Novartis	TASIGNA	nilotinib hydrochloride

Key insights for pharmaceutical patentability - Austria patent ATE514689

Last updated: April 26, 2026

ATE514689 in Austria: Scope, Claims, and Patent-Landscape View

Summary: No complete, verifiable patent document identifying “ATE514689” as an Austria drug patent could be produced from authoritative patent repositories at the time of writing. Without a match to a published Austrian patent application/grant or an EU/EP family member with a corresponding publication number, a legally grounded scope-and-claims analysis cannot be completed and therefore is not provided.

What is ATE514689 in the Austrian patent system?

A complete scope and claims analysis requires at minimum one of the following: a valid publication number (e.g., AT, WO, EP publication), an applicant/assignee name, an exact title, a filing date, or a patent family link. “ATE514689” does not map to a specific Austrian publication-grant record with a stable identifier suitable for claim parsing and landscape construction.

Are there Austrian claims available to parse?

Claims and scope require direct access to the legally published claim set for the identified instrument (AT publication/grant or a tied WO/EP publication with an Austria validation). With no resolvable document behind “ATE514689,” no claim text can be cited, claim categories (composition, process, use, formulation, dosing, polymorph, salt, device) cannot be classified, and no claim-to-therapeutic or manufacturing coverage can be structured.

What does the patent landscape look like without the document match?

Landscape mapping depends on:

• The target family (priority chain, jurisdictional coverage, continuations/divisionals)
• Expiration and status in key jurisdictions
• Cited prior art and claim-defining distinctions
• Related formulations and salt/polymorph branches
• Orange Book style equivalents (if relevant), and authority registries

No such structure can be built without a resolved identifier.

---

Key Takeaways

• A scope-and-claims and Austria landscape analysis is not provided because “ATE514689” cannot be tied to a specific, citable Austrian or linked EP/WO publication record.
• No claim coverage, validity-risk framing, or freedom-to-operate structure can be generated without a resolvable document.

---

FAQs

1) Can you analyze claim scope without the exact AT publication number?

No. Claim scope requires the published claim set tied to a specific identifier.

2) Is “ATE514689” likely an internal code rather than a publication number?

It may be, but without a resolvable public record, the mapping cannot be executed.

3) Can you infer scope from the drug name only?

Not in a legally actionable way. Scope depends on claim language and priority-linked family structures.

4) Can you list related patents in Austria if you cannot identify the family?

No. Landscape construction requires a resolved family tree.

5) What would be needed to produce an accurate claim and landscape analysis?

A specific, citable publication/grant record (AT/WO/EP number) or an unambiguous family link.

---

References

[1] European Patent Register (EPO). Patent publication and bibliographic data search portal. https://register.epo.org/